Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Pembrolizumab
Treatment for Malignant skin melanoma
Typical Dosage: 200mg IV every 3 weeks or 400mg IV every 6 weeks
Effectiveness
88%
Safety Score
35%
Clinical Trials
65
Participants
12K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
35
DangerousModerateSafe
Treatment Details
Dosage Range
200mg IV every 3 weeks or 400mg IV every 6 weeks
Time to Effect
3-6 months
Treatment Duration
1-2 years
Evidence Quality
HIGHConfidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$170,000
Monitoring:$15,000
Side Effect Mgmt:$10,000
Total Annual:$195,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$180,000/QALY
QALYs Gained
2
Outcome-Based Costs
Cost per Responder
$487,500
Cost per Remission
$1,300,000
Comparison vs Ipilimumab
Cost Difference
+$70,000/year
More expensive
QALY Difference
+0.50 QALYs
Better outcomes
Dominance
No dominance
Pembrolizumab Outcomes
for Malignant skin melanoma
Efficacy Outcomes
Overall Effectiveness
+88%
Response Rate
+40%
Remission Rate
+15%
Common Side Effects
Fatigue
+40%
Pruritus (itchiness)
+30%
Diarrhea
+20%
Rash
+20%
Nausea
+20%
Immune-related adverse events
+15%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
3 active trials recruiting for Pembrolizumab in Malignant skin melanoma
A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
NCT06961006RECRUITINGPHASE2
160 participants
INTERVENTIONAL
Springdale, United States +37 more
Started: May 29, 2025
Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss
NCT03131908ACTIVE NOT RECRUITINGPHASE1, PHASE2
27 participants
INTERVENTIONAL
Houston, United States
Started: Jul 17, 2017
Melanoma Metastasized to the Brain and Steroids
NCT03563729RECRUITINGPHASE2
80 participants
INTERVENTIONAL
Herlev, Denmark +2 more
Started: Jun 6, 2018
Completed Clinical Trials
14 completed trials for Pembrolizumab in Malignant skin melanoma
A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma
NCT02434354COMPLETEDPHASE1
33 participants
INTERVENTIONAL
Philadelphia, United States
Started: Apr 1, 2015
Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
NCT02902042COMPLETEDPHASE1, PHASE2
16 participants
INTERVENTIONAL
Freiburg im Breisgau, Germany +10 more
Started: Apr 24, 2018
Co-stimulatory Markers and Vitamin D Status in Anti-PD1 Treated Melanoma Patients
NCT03197636COMPLETED
40 participants
OBSERVATIONAL
Aarhus, Denmark
Started: Aug 11, 2017
Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Participants With Advanced Melanoma
NCT03084640COMPLETEDPHASE1
30 participants
INTERVENTIONAL
Los Angeles, United States +3 more
Started: May 4, 2017
Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study
NCT04889118COMPLETEDPHASE3
131 participants
INTERVENTIONAL
Beijing, China +10 more
Started: Jul 14, 2020
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002)
NCT01704287COMPLETEDPHASE2
540 participants
INTERVENTIONAL
Started: Nov 20, 2012
Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)
NCT03820986COMPLETEDPHASE3
674 participants
INTERVENTIONAL
Los Angeles, United States +118 more
Started: Mar 12, 2019
4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy
NCT03278665COMPLETEDPHASE1, PHASE2
40 participants
INTERVENTIONAL
Essen, Germany +6 more
Started: Sep 25, 2017
IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic Melanoma
NCT07436390COMPLETEDNA
132 participants
INTERVENTIONAL
Ljubljana, Slovenia
Started: Mar 31, 2024
Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma
NCT02574533COMPLETEDPHASE1
2 participants
INTERVENTIONAL
Abilene, United States +2 more
Started: Oct 1, 2015
Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma
NCT02816021COMPLETEDPHASE2
24 participants
INTERVENTIONAL
Houston, United States
Started: Feb 14, 2017
Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma
NCT05304546COMPLETEDPHASE2
1 participants
INTERVENTIONAL
Ramat Gan, Israel
Started: Sep 5, 2023
Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma
NCT02306850COMPLETEDPHASE2
10 participants
INTERVENTIONAL
St Louis, United States
Started: Jan 1, 2015
UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma
NCT03538314COMPLETEDPHASE1
30 participants
INTERVENTIONAL
Santa Monica, United States +3 more
Started: Jul 9, 2018
Showing 20 of 67 total trials